• Chloroquine-resistant falciparum malaria (alone or with pyrimethamine and a sulfonamide or with a tetracycline; has also been used with clindamycin and mefloquine depending on origin of illness).

Contraindicated in:

• Hypersensitivity to quinine, quinidine, or mefloquine
• History of previous serious adverse reaction to quinine including thrombotic thrombocytopenic purpura, thrombocytopenia, acute intravascular hemolysis, hemoglobinuria, or hemoglobinemia
• QTc prolongation or conditions predisposing to QTc prolongation including hypokalemia and bradycardia
• Concurrent use of Class IA or Class III antiarrhythmics, mefloquine, pimozide, or macrolide anti-infectives (↑ risk of arrhythmias)
• Myasthenia gravis
• Optic neuritis
• Severe hepatic impairment.

Use Cautiously in:

• Glucose–6–phosphate deficiency (↑ risk hemolysis)
• Recurrent or interrupted malaria therapy
• History of arrhythmias, especially QTc prolongation
• Atrial fibrillation/flutter (may cause paradoxical ↑ in ventricular response)
• Hypoglycemia
• History of thrombocytopenic purpura
• Mild or moderate hepatic impairment
• OB: Use only if potential maternal benefit justifies potential fetal risk; may ↑ risk of hypoglycemia in mother especially during 3rd trimester
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Children <16 yr (safety and effectiveness not established).

CV: PR interval prolongation, QT interval prolongation, TORSADES DE POINTES.

Derm: rash, STEVENS-JOHNSON SYNDROME.

Endo: hypoglycemia.

GI: abdominal cramps/pain, diarrhea, nausea, vomiting, hepatotoxicity.

GU: ↓fertility (males).

Hemat: bleeding, blood dyscrasias, hemolytic anemia, HEMOLYTIC UREMIC SYNDROME, THROMBOCYTOPENIA, THROMBOTIC THROMBOCYTOPENIC PUPURA.
Misc: cinchonism, (INCLUDING ANAPHYLAXIS AND FEVER)HYPERSENSITIVITY REACTIONS .

Drug-Drug:

• Concurrent use of Class IA antiarrhythmics (quinidine, procainamide, disopyramide, Class III antiarrhythmics, mefloquine, pimozide, or macrolide anti-infectives ↑ risk of arrhythmias and should be avoided.
• Antacids containing aluminum or magnesium↓ absorption; avoid concurrent use.
• Cimetidine, ketoconazole, ritonavir, tetracycline, theophylline, and erythromycin may ↑ levels; avoid concurrent use with erythromycin or ritonavir.
• Rifampin and rifabutin may ↓ levels; avoid concurrent use with rifampin.
• May ↑ effects of neuromuscular blocking agents.
• May ↑ risk of hemolytic, ototoxic, or neurotoxic reactions when used concurrently with agents sharing these toxicities.
• Concurrent use with mefloquine↑ risk of seizures and adverse cardiovascular reactions.
• Urinary alkalinizers including acetazolamide and sodium bicarbonate may ↑ blood levels.
• May ↑ levels of carbamazepine, phenobarbital, atorvastatin, simvastatin, lovastatin, desipramine, dextromethorphan, digoxin, and warfarin.
• Carbamazepine, phenobarbital, and phenytoin may ↓ levels.

(Generic available)

• Capsules: 200 mg; 300 mg; 324 mg;

• PO (Adults): 648 mg every 8 hr for 7 days.

Qualaquin

• Disrupts metabolism of the erythrocytic phase of Plasmodium falciparum.
• Increases the refractory period of skeletal muscle, increases the distribution of calcium within muscle fibers, decreases the excitability of motor end-plate regions, resulting in decreased response to repetitive nerve stimulation and acetylcholine.

• Death of P. falciparum.

Therapeutic Classification: antimalarials

Absorption: Rapidly and almost completely (80%) absorbed following oral administration.

Distribution: Varies with condition and patient; does not enter CSF well. Crosses the placenta and enters breast milk.

Protein Binding: >90% in patients with cerebral malaria, pregnant women, and children; 85–90% in patients with uncomplicated malaria; 70% in healthy adults.

Metabolism/Excretion: >80% metabolized by the liver; metabolites have less activity than quinine; metabolites excreted in urine. 20% excreted unchanged in urine. Excretion ↑ in acidic urine.

Half-life: 11 hr (↑ in patients with malaria).

(antimalarial blood levels)

• Instruct patient to take medication as directed and continue full course of therapy, even if feeling better. Take missed doses as soon as remembered, unless almost time for the next dose. If more than 4 hr has elapsed since missed dose, wait and take the next dose as scheduled. Do not double doses or take more than recommended. Advise patient to read the Patient Information leaflet prior to starting therapy and with each Rx refill.
• Review methods of minimizing exposure to mosquitoes with patients receiving quinine (use insect repellent, wear long-sleeved shirt and long trousers, use screen or netting).
• Quinine may cause visual changes. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
• May cause diarrhea, nausea, stomach cramps or pain, vomiting, or ringing in the ears. Advise patient to notify health care professional promptly if these become pronounced.
• Advise patient to stop quinine and notify health care professional of any evidence of allergy (flushing, itching, rash, fever, facial swelling, stomach pain, difficult breathing, ringing in the ears, visual problems) or rash.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

KWI-nine